TP032/#1532 Oregovomab and non-platinum single agent chemotherapy in parp inhibitor-resistant ovarian cancer patients not candidate for platinum retreatment: a multi-cohort phase II study (KGOG 3065/APGOT-OV6). (4th December 2022)

• Record Type: Journal Article
• Authors: Lee, Young Joo; Lee, Jung-Yun; Park, Junsik; Lee, Yong Jae; Kim, Sunghoon; Lee, Yoo-Young; Choi, Chel Hun; Kim, Byoung-Gie; Kim, Hee Seung; Kim, Jae-Weon; Jada, Srinivasa
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A239
• Page End: A239
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.541
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Oregovomab is an investigational murine monoclonal antibody directed against Cancer Antigen 125(CA-125), currently in clinical trials for treatment of patients with ovarian cancer expressing the tumor-associated cancer antigen CA-125. Outcomes are poor with non-platinum single agent chemotherapy in Poly-ADP Ribose Polymerase (PARP) inhibitor and platinum resistant setting. The aim of this study is to determine the efficacy of the indirect immunization with oregovomab in combination with non-platinum single agent chemotherapy in PARP inhibitor-resistant recurrent ovarian cancer patients not candidate for platinum retreatment. Methods: This is a prospective, multi-cohort, multicenter, phase II trial to evaluate the efficacy and safety of oregovomab in combination with non-platinum single agent chemotherapy in patients with recurrent epithelial ovarian cancer who have progressed with prior PARP inhibitor treatment and not candidate for platinum re-challenge. Patients were assigned to one of the followings: Cohort 1 (prior 1–3 lines of therapy), PLD (40 mg/m 2 q4w till PD) + Oregovomab 2 mg (C1, 2, 3, 5, 7 for 5 doses) or Cohort 2 (>3 prior lines of therapy), weekly paclitaxel (80 mg/m 2 D1, 8, 15 q4w till PD) + Oregovomab 2 mg (C1, 2, 3, 5, 7 for 5 doses). A total 56 subjected will be enrolled from 4 sites in South Korea. The primary endpoint is objective response rate. Accrual is expected to be started in July 2022. Results: Trial in progress: there are no available results at the time of submission. Conclusions: Trial in progress: there are no available results at the time of submission.